Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol-Myers Squibb news coverage encompasses regulatory developments, clinical trial results, product launches, business transactions, and corporate initiatives. The company's activities across oncology, hematology, immunology, cardiovascular, and neuroscience generate frequent updates that impact stakeholders in the healthcare and investment communities.
Regulatory announcements represent significant news events for Bristol-Myers Squibb, including approvals of new medicines, expanded indications for existing products, and regulatory submissions in various markets. These milestones reflect the progression of the company's pipeline from clinical development through regulatory review to market authorization. Priority review designations, breakthrough therapy designations, and orphan drug designations also generate news coverage as indicators of regulatory progress.
Clinical trial data releases occur at medical conferences, in peer-reviewed publications, and through corporate announcements. Results from pivotal trials evaluating new medicines or expanded uses of approved products receive particular attention from the medical community and investors. The company's extensive clinical trial portfolio across multiple therapeutic areas produces a steady stream of data readouts that inform understanding of product profiles and market potential.
Business development activities including acquisitions, licensing agreements, research collaborations, and strategic partnerships shape Bristol-Myers Squibb's long-term direction. These transactions can bring new assets into the pipeline, provide access to novel technologies, or establish collaborations with academic institutions and biotechnology companies. Divestitures and portfolio prioritization decisions also generate news coverage.
Commercial performance updates occur through periodic financial reporting and corporate presentations. These updates provide insight into product uptake, market penetration, competitive dynamics, and the impact of healthcare policy changes on business results. Manufacturing capacity expansions, supply chain developments, and commercial launches in new geographic markets represent additional categories of business news.
Corporate initiatives related to sustainability, patient access, health equity, research funding, and community engagement reflect broader aspects of Bristol-Myers Squibb's operations beyond drug development and commercialization. Leadership changes, organizational restructuring, and strategic priority shifts also contribute to news flow.
Bristol Myers Squibb (NYSE:BMY) announced positive two-year results from the POETYK PSO long-term extension trial for Sotyktu™ (deucravacitinib), showing maintained efficacy in treating moderate-to-severe plaque psoriasis. Response rates at 112 weeks were 82.4% for PASI 75 and 55.2% for PASI 90. The data were presented at the 2022 European Academy of Dermatology and Venereology Congress, underscoring the company's commitment to dermatology research. These findings support Sotyktu’s role as a promising oral therapy for patients with psoriasis.
Bristol Myers Squibb's Sotyktu™ (deucravacitinib) has received FDA approval as the first oral, selective TYK2 inhibitor for adults with moderate-to-severe plaque psoriasis, marking a significant innovation in treatment options after nearly a decade. The approval follows successful Phase 3 POETYK PSO clinical trials, which showed Sotyktu's superior efficacy over placebo and Otezla® in achieving skin clearance. This breakthrough therapy is anticipated to set a new standard of care and will be available to patients starting September 2022.
Bristol Myers Squibb (NYSE: BMY) is launching its annual Coast 2 Coast 4 Cancer ride, starting from Cannon Beach, Oregon and ending in Long Branch, New Jersey on October 3. Over 126 employees will participate to raise awareness and funding for the V Foundation for Cancer Research. The event has raised over $9.83 million since its inception in 2014, with a target of surpassing $1 million this year. Participants include cancer survivors and those riding in memory of loved ones, with Bristol Myers Squibb matching donations up to $500,000.
Bristol Myers Squibb (NYSE:BMY) will announce its third-quarter 2022 financial results on October 26, 2022, during a conference call at 8:00 a.m. ET. The call will include a review of the financial results and a Q&A session with investors and analysts. A live webcast is available for the public at investor.bms.com. The call can also be accessed via phone by dialing 877-502-9276 in the U.S. Participants can replay the call starting 11:30 a.m. ET on the same day until November 9, 2022.
Bristol Myers Squibb (NYSE: BMY) will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 8:10 a.m. ET in New York City. Executive Vice Presidents Chris Boerner, Ph.D., and Samit Hirawat, M.D., will address questions regarding the company's operations. A live webcast will be accessible at investor.bms.com, with an archived version available later that day.
Bristol Myers Squibb focuses on developing innovative medicines for serious diseases.
Bristol Myers Squibb (NYSE: BMY) presented significant research at the ESMO Congress 2022, underscoring the impact of Opdivo (nivolumab) in treating various cancers. Key findings include positive long-term survival data from Opdivo-based therapies and supportive evidence for its combination with other agents in advanced melanoma, non-small cell lung cancer, and urothelial carcinoma. Over 90 studies will be showcased, emphasizing the ongoing commitment to cancer treatment and personalized medicine.
Bristol Myers Squibb (NYSE: BMY) will participate in Citi’s 17th Annual BioPharma Conference on September 8, 2022, in Boston, Massachusetts. The session is scheduled for 8:50 a.m. ET, where company executives will address questions regarding the firm. Investors and the public can listen to a live webcast of the event on BMS.com, with an archived version available later the same day. Bristol Myers Squibb is dedicated to developing innovative medicines to combat serious diseases.
Bristol Myers Squibb (NYSE:BMY) reported promising results from the Phase 2 AXIOMATIC-SSP study on milvexian, an oral factor XIa inhibitor, showing a ~30% relative risk reduction in symptomatic ischemic strokes compared to placebo. Notably, there were no instances of fatal bleeding or increased symptomatic intracranial hemorrhage among patients treated with milvexian. These findings suggest potential for milvexian in improving outcomes for stroke patients, warranting further Phase 3 studies.
Bristol Myers Squibb (NYSE:BMY) has completed its acquisition of Turning Point Therapeutics in an all-cash deal valued at $76 per share. This acquisition enhances BMY's oncology portfolio, particularly with Turning Point’s lead asset, repotrectinib, aimed at ROS1-positive non-small cell lung cancer patients. The drug has shown promising results in clinical trials and is expected to receive FDA approval in the second half of 2023. Approximately 84% of Turning Point’s shares were tendered in the offer, finalizing its status as a wholly owned subsidiary of BMY.
Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) announced the expiration of the waiting period under the HSR Act, receiving merger control clearance from the Federal Cartel Office of Germany. The acquisition offer to buy all outstanding shares of Turning Point for $76.00 per share, totaling approximately $4.1 billion, is set to close on August 17, 2022. Approximately 41.9 million shares, or 84% of Turning Point's outstanding shares, were validly tendered as of the Offer's expiration on August 15, 2022.
FAQ
What is the current stock price of Bristol-Myers Squibb Co (BMY)?
What is the market cap of Bristol-Myers Squibb Co (BMY)?
